West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short

Azenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.

West Pharmaceutical Services (WST) reported Q2 adjusted EPS of $2.37, up 28.8% and 13.9% above consensus, on revenue of $872.3 million, up 13.8% and above consensus. The company raised 2026 revenue guidance to $3.345B-$3.380B and adjusted EPS to $8.85-$9.05, citing stronger HVP growth and wider margins.

West Pharmaceutical Services reported higher Q2 2026 sales and earnings, raised its full-year 2026 revenue outlook, completed a US$454.28 million share repurchase, and kept its US$0.22 quarterly dividend. It also expanded a Daikyo Seiko distribution deal via new 10-year agreements, granting West exclusivity outside Japan and expanding Daikyo’s role in Japan.

West Pharmaceutical Services reported Q2 2026 results driven by 16% organic growth in Proprietary Products, including a 29% rise in Biologics. High-Value Product components rose to 49% of revenue. Full-year 2026 organic growth guidance was raised to 10% to 11%, with margin expansion expected. SmartDose divestiture and a May cyber incident were cited.

West Pharmaceutical Services (NYSE:WST) reported Q2 revenue of $872 million, up 13% organically, and adjusted EPS of $2.37, up 29% year over year. The company raised its 2026 outlook to $3.345 billion-$3.38 billion revenue and adjusted EPS of $8.85-$9.05, citing strong high-value product components demand tied to biologics and GLP-1 elastomers, plus margin expansion and buybacks.

West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 revenue of $872.3 million, up 13.8% year on year and above market expectations by 3.5%, according to the company. Non-GAAP EPS was $2.37, 13.9% above consensus. Next-quarter revenue guidance midpoint was $827.5 million. Shares rose about 7.3% to $384.97 after results.